Compare BOE & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOE | ARVN |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 649.4M | 600.2M |
| IPO Year | N/A | 2018 |
| Metric | BOE | ARVN |
|---|---|---|
| Price | $11.35 | $7.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 15 |
| Target Price | N/A | ★ $14.54 |
| AVG Volume (30 Days) | 166.4K | ★ 679.4K |
| Earning Date | 01-01-0001 | 11-03-2026 |
| Dividend Yield | ★ 7.30% | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | N/A | ★ 1.70 |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | N/A | $12.96 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $4.65 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.59 | $6.74 |
| 52 Week High | $12.58 | $14.22 |
| Indicator | BOE | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 39.11 | 48.35 |
| Support Level | $11.14 | $6.74 |
| Resistance Level | $11.99 | $7.77 |
| Average True Range (ATR) | 0.17 | 0.36 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 30.65 | 62.79 |
Blackrock Enhanced Global Dividend Trust is a closed-end management investment company. Its investment objective is to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. The Trust seeks to achieve its investment objectives by investing in equity securities issued by companies located in countries throughout the world.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.